Filter Results:
(994)
Show Results For
- All HBS Web
(994)
- People (4)
- News (257)
- Research (615)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(994)
- People (4)
- News (257)
- Research (615)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
- 1996
- Chapter
The Determinants of Research Productivity in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
- November 2018
- Case
Aura Biosciences: Bringing a Breakthrough Drug to Market
By: Robert J. Dolan and Navid Mojir
- Article
Measuring Competence? Exploring Firm Effects in Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
Henderson, Rebecca M., and Ian Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Strategic Management Journal 15 (Winter 1994): 63–84. (Winner of Dan and Mary Lou Schendel Best Paper Prize To honor substantial work published in the Strategic Management Journal presented by Strategic Management Society.)
- November 2018
- Case
David Hysong and SHEPHERD Therapeutics
By: Ananth Raman, John Masko and Aldo Sesia
In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his... View Details
- 01 Mar 2004
- News
Drug Imports a Hot Topic at Alumni Health-Care Conference
FDA Commissioner Mark B. McClellan doesn’t approve of Americans buying low-cost prescription drugs from Canada or over the Internet. But he understands what drives them to do so. At the HBS Health Industry Alumni Association’s fourth... View Details
- August 2012 (Revised August 2024)
- Case
ABC Pharmaceuticals
By: Regina E. Herzlinger and Erik R. Sparks
This case asks students to price a new drug that is in Stage II of its clinical trials. It contains detailed estimates of the time required and costs for all the steps needed to commercialize a drug in the U.S. Students will learn virtually all the steps required to... View Details
Keywords: Drug Development; Price; Product; Product Launch; Health Industry; Technology Industry; Pharmaceutical Industry
Herzlinger, Regina E., and Erik R. Sparks. "ABC Pharmaceuticals." Harvard Business School Case 313-041, August 2012. (Revised August 2024.)
- September 2022
- Article
Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities
By: Leemore Dafny, Christopher Ody and Teresa Rokos
The federal Anti-Kickback Statute prohibits biopharmaceutical manufacturers from directly covering Medicare enrollees’ out-of-pocket spending for the drugs they manufacture, but manufacturers may donate to independent patient assistance charities and earmark donations... View Details
Keywords: Cost Sharing; Prescription Drugs; Drug Spending; Medicare; Dual Eligibility; Cost; Health Care and Treatment; Philanthropy and Charitable Giving; Pharmaceutical Industry
Dafny, Leemore, Christopher Ody, and Teresa Rokos. "Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities." Health Affairs 41, no. 9 (September 2022).
- Article
Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users
By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details
Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States
Stern, Ariel Dora, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup, and Ernst R. Berndt. "Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users." Health Affairs 40, no. 6 (June 2021): 989–999.
- Fast Answer
Pharmaceuticals: drug approval dates in the UK and Europe
Where can I find drug approval dates for the UK? The European Medicines Agency provides information on drug approvals in the UK and Europe: EMA Annual Reports and Work Programmes provides list of new... View Details
- June 2025
- Teaching Note
Market Dynamics and Moral Dilemmas: Novo Nordisk's Weight Loss Drugs
Teaching Note for HBS Case No. 324-114. View Details
- December 2000
- Case
Drug Wars, The: Pfizer's Hostile Bid for Warner-Lambert in 1999
By: Stephen P. Bradley and Matthew Sandoval
Describes Pfizer's hostile bid for Warner-Lambert in the fall of 1999. Allows for an evaluation of the possible synergies created and poses the question as to whether Pfizer will pay too much. View Details
Bradley, Stephen P., and Matthew Sandoval. "Drug Wars, The: Pfizer's Hostile Bid for Warner-Lambert in 1999." Harvard Business School Case 701-009, December 2000.
- 03 Apr 2015
- News
The Apple Watch: A gateway drug for Swiss horology
- 08 Aug 2023
- News
The Weight-Loss Drug Frenzy Is Outrunning the Company Behind It
- 08 Jul 2019
- News
What the U.S. can learn from Germany on drug prices
- November 1969 (Revised February 1973)
- Background Note
Note on the U.S. Prescription Drug Industry, Part II
By: Hugo Uyterhoeven and Audrey T. Sproat
Uyterhoeven, Hugo, and Audrey T. Sproat. "Note on the U.S. Prescription Drug Industry, Part II." Harvard Business School Background Note 370-039, November 1969. (Revised February 1973.)
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details
Keywords: Cost vs Benefits; Decisions; Judgments; Values and Beliefs; Global Strategy; Health Care and Treatment; Patents; Growth and Development Strategy; Growth Management; Product Positioning; Supply and Industry; Supply Chain; Corporate Social Responsibility and Impact; Mission and Purpose; Philanthropy and Charitable Giving; Opportunities; Social Issues; Equality and Inequality; Pharmaceutical Industry; Health Industry; Denmark; United States; Europe; China; India; Middle East; North Africa
Badaracco, Joseph L., Tom Quinn, and John Schultz. "Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs." Harvard Business School Case 324-114, April 2024. (Revised July 2024.)
- 17 Jul 2013
- News